INTRODUCTION Worldwide, it is estimated that about 1.3 million new gynecological cancer cases are diagnosed each year. For 2018, the predicted annual totals were cervix uteri 569,847, corpus uteri 382,069, ovary 295,414, vulva 44,235 and va​gina 17,600. Treatments include hysterectomy with or without bilateral salpingo-oophorectomy, radiotherapy and chemotherapy. These can result in loss of ovarian function and, in women under the age of 45, early menopause. AIM The aim of this position statement is to set out an individualized approach to the management, with or without menopausal hormone therapy, of menopausal symptoms and the prevention and treatment of osteoporosis in women with gynecological cancer. MATERIALS AND METHODS Literature review and consensus of expert opinion. SUMMARY RECOMMENDATIONS The limited data suggest that women with low-grade, early-stage endometrial cancer may consider systemic or topical estrogens. However, menopausal hormone therapy may stimulate tumor growth in patients with more advanced disease, and non-hormonal approaches are recommended. Uterine sarcomas may be hormone dependent, and therefore estrogen and progesterone receptor testing should be undertaken to guide decisions as to whether menopausal hormone therapy or non-hormonal strategies should be used. The limited evidence available suggests that menopausal hormone therapy, either systemic or topical, does not appear to be associated with harm and does not decrease overall or disease-free survival in women with non-serous epithelial ovarian cancer and germ cell tumors. Caution is required with both systemic and topical menopausal hormone therapy in women with serous and granulosa cell tumors because of their hormone dependence, and non-hormonal options are recommended as initial therapy. There is no evidence to contraindicate the use of systemic or topical menopausal hormone therapy by women with cervical, vaginal or vulvar cancer, as these tumors are not considered to be hormone dependent.

中文翻译：

---

欧洲更年期和男性更年期协会 (EMAS) 和国际妇科癌症协会 (IGCS) 关于管理妇科癌症后更年期的立场声明：关注更年期症状和骨质疏松症

引言 在全球范围内，估计每年诊断出约 130 万例新的妇科癌症病例。对于 2018 年，预测的年总数为子宫颈 569,847、子宫体 382,​​069、卵巢 295,414、外阴 44,235 和阴道 17,600。治疗包括子宫切除术，伴或不伴双侧输卵管卵巢切除术、放疗和化疗。这些可能导致卵巢功能丧失，并且在 45 岁以下的女性中，更年期提前。目的 本立场声明的目的是制定个体化的方法来管理更年期症状和预防和治疗妇科癌症女性骨质疏松症，无论是否使用绝经激素治疗。材料与方法 文献回顾和专家意见共识。总结建议 有限的数据表明，患有低级别、早期子宫内膜癌的女性可以考虑全身或局部使用雌激素。然而，绝经期激素治疗可能会刺激更晚期疾病患者的肿瘤生长，因此建议使用非激素治疗。子宫肉瘤可能是激素依赖性的，因此应进行雌激素和孕激素受体检测以指导决定是否应使用更年期激素治疗或非激素策略。可用的有限证据表明，绝经期激素治疗，无论是全身性的还是局部的，似乎与伤害无关，并且不会降低患有非浆液性上皮性卵巢癌和生殖细胞肿瘤的女性的总体或无病生存率。对患有浆液性和颗粒细胞瘤的女性进行全身性和局部绝经期激素治疗都需要谨慎，因为它们具有激素依赖性，建议将非激素选择作为初始治疗。没有证据表明宫颈癌、阴道癌或外阴癌患者使用全身性或局部绝经期激素治疗是禁忌，因为这些肿瘤不被认为是激素依赖性的。